Oncology News | pharmaphorum

News

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson,

News

New bill moves to tighten accelerated approval regulation in...

US House Energy & Commerce Committee Chair Frank Pallone (D-NJ) has introduced a new bill to enhance the Food and Drug Administration’s (FDA) authority to ensure products that receive a

News

The data are in – so will Gilead's Trodelvy achieve its pote...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

News

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

Bristol-Myers Squibb's Opdivo has been playing second fiddle to Merck & Co's Keytruda in the non-small cell lung cancer (NSCLC) market for years, but now it has a chance to take the lim

News

Sanofi makes another pipeline deal, tapping Adagene for anti...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therap

News